Literature DB >> 3159721

Activation of muscle phosphofructokinase by fructose 2,6-bisphosphate and fructose 1,6-bisphosphate is differently affected by other regulatory metabolites.

K Tornheim.   

Abstract

Fructose-2,6-P2 and fructose-1,6-P2 are strong activators of muscle phosphofructokinase. They have been shown to be competitive in binding studies, and it is generally thought that they affect the physical and catalytic properties of the enzyme in the same manner. However, there are indications in published data that the effects of the two fructose bisphosphates on phosphofructokinase are not identical. To examine this possibility, the kinetics of activation of rat skeletal muscle phosphofructokinase by the two fructose bisphosphates were compared in the presence of other regulatory metabolites. Citrate greatly increased the K0.5 of the enzyme for fructose-2,6-P2, with little effect on the maximum activation. In contrast, citrate greatly decreased the maximum activation by fructose-1,6-P2, with only a small effect on the K0.5. Changes in the concentrations of the inhibitor ATP or the activator AMP similarly altered the K0.5 for fructose-2,6-P2, but altered the maximum activation by fructose-1,6-P2. Finally, when fructose-1,6-P2 was added in the presence of a given concentration of fructose-2,6-P2, phosphofructokinase activity was decreased if the activation by fructose-2,6-P2 alone was greater than the maximum activation by fructose-1,6-P2 alone. These results are consistent with competition of the two fructose bisphosphates for the same binding site, but indicate that the conformational changes produced by their binding are different.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Oscillations in oxygen consumption by permeabilized clonal pancreatic beta-cells (HIT) incubated in an oscillatory glycolyzing muscle extract: roles of free Ca2+, substrates, and the ATP/ADP ratio.

Authors:  V N Civelek; J T Deeney; G E Fusonie; B E Corkey; K Tornheim
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

2.  Inositol 1,4-bisphosphate is an allosteric activator of muscle-type 6-phosphofructo-1-kinase.

Authors:  G W Mayr
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

3.  Slow oscillations persist in pancreatic beta cells lacking phosphofructokinase M.

Authors:  Isabella Marinelli; Vishal Parekh; Patrick Fletcher; Benjamin Thompson; Jinhua Ren; Xiaoqing Tang; Thomas L Saunders; Joon Ha; Arthur Sherman; Richard Bertram; Leslie S Satin
Journal:  Biophys J       Date:  2022-02-05       Impact factor: 4.033

Review 4.  Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise.

Authors:  U Krause; G Wegener
Journal:  Experientia       Date:  1996-05-15

5.  Subunit interactions and composition of the fructose 6-phosphate catalytic site and the fructose 2,6-bisphosphate allosteric site of mammalian phosphofructokinase.

Authors:  Cristina Ferreras; Eloy D Hernández; Oscar H Martínez-Costa; Juan J Aragón
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

6.  Changes in glucose 1,6-bisphosphate content in rat skeletal muscle during contraction.

Authors:  A M Bassols; J Carreras; R Cussó
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

7.  A model of phosphofructokinase and glycolytic oscillations in the pancreatic beta-cell.

Authors:  Pål O Westermark; Anders Lansner
Journal:  Biophys J       Date:  2003-07       Impact factor: 4.033

8.  Antagonistic effects of hexose 1,6-bisphosphates and fructose 2,6-bisphosphate on the activity of 6-phosphofructokinase purified from honey-bee flight muscle.

Authors:  G Wegener; H Schmidt; A R Leech; E A Newsholme
Journal:  Biochem J       Date:  1986-06-15       Impact factor: 3.857

9.  Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.

Authors:  Khalid O Alfarouk; Daniel Verduzco; Cyril Rauch; Abdel Khalig Muddathir; H H Bashir Adil; Gamal O Elhassan; Muntaser E Ibrahim; Julian David Polo Orozco; Rosa Angela Cardone; Stephan J Reshkin; Salvador Harguindey
Journal:  Oncoscience       Date:  2014-12-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.